CAC Partner Links

Corporate Advisory Council

MHI’s relationship with the Corporate Advisory Council is built on mutual respect, transparency, and a shared commitment to advancing the organization’s mission while addressing the corporate partners’ interests and needs. This council comprises of seasoned professionals from various industries who offer strategic guidance, financial support, and access to valuable networks. Through this partnership, both parties can amplify their impact and create positive change in the lives of heart patients, their families and caregivers nationwide.

Check here often for the latest on clinical trials, clinical devices, and new drugs.

• The Triton Studies for individuals with ATTR Amyloidosis: https://tritonstudies.com/
• FDA Approval of vutrisiran:  https://investors.alnylam.com/press-release?id=28831
• Plain Language Summary:  Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: https://www.tandfonline.com/doi/epdf/10.1080/14796678.2025.2493019
• KARDIA-2 Topline Study Results

• Amgen’s Bold Ambition: To Halve Cardiovascular Events in the U.S. by 2030

• Welcome to Bayer Clinical Trials
• Bayer United States of America – Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress (q4web.com)
• Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA® (finerenone) in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction | Business Wire. Bayer will have social media forthcoming regarding this announcement in the hours and days ahead (Bayer US Corporate X Channel; Bayer Pharma LinkedIn)
• ESC 2024: Late-Breaking KERENDIA® (Finerenone) Investigational Data Showed a Statistically Significant Reduction in the Composite Outcome of Cardiovascular Death and Total Heart Failure Events in Adult Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The findings were also published in the New England Journal of Medicine.
• Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024 | Business Wire
• Bayer United States of America – U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
• Bayer United States of America – U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review

• Bristol Myers Squibb and Pfizer announce Direct-to-Patient Eliquis^® Option

• https://www.kardigan.bio/press-release/kardigan-launches-with-industry-leading-team-to-modernize-cardiovascular-drug-development-with-late-stage-portfolio-of-personalized-medicines/
• https://www.linkedin.com/posts/kardigan-inc_cvd-cvbiotech-activity-7376964414937284608-c0S1?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEopf0QBQYJklaCKte9y06K3i8ZTaIsvRLc
• Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis

• Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

• Bristol Myers Squibb (BMS) announces new study that is currently enrolling adolescents ages 12 to 17 who have obstructive hypertrophic cardiomyopathy (HCM). Current treatment can continue during the study. There’s no cost to participate in SCOUT-HCM. Charges for standard of care treatment might still apply. Qualified participants may also receive travel reimbursement.

• • MAPLE-HCM: Phase 3 trial to evaluate the efficacy and safety of Aficamten compared to metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy (HCM). For more information about this clinical trial, please click HERE

• • Following the topline results announced earlier this year, Cytokinetics has issued a press release announcing the full results from ACACIA-HCM, the pivotal Phase 3 clinical trial investigating aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), which you can find linked here. The results were published in the peer-reviewed publication, The New England Journal of Medicine.  Aficamten is not approved for the treatment of patients with nHCM, and the safety and efficacy have not been established.  MYQORZO® (aficamten) is only approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

• Edgewise Therapeutics is conducting the CIRRUS-HCM study to learn about the safety and tolerability of an investigational drug called EDG-7500 for individuals with obstructive or nonobstructive HCM. This study is taking place at multiple trial sites across the US for individuals who are 18-85 years old, have been diagnosed with obstructive or nonobstructive HCM, and are not currently taking a cardiac myosin inhibitor (CMI). For more information, visit https://clinicaltrials.gov/study/NCT06347159

• Journal of Economics. Plain Language Summary TAVR and the Value of Increasing Treatment

• Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
• FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

• Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia